IRulya Therapeutics closed at $39.78 on Nov 12, up 3.78%, 1.2% below its highest close since Oct 12. Volume of 138.3K shares was 1.38× its 20-day average (above normal).
Split-adjusted performance: +32.6% over one month.
Short interest was 127.8K shares at the Oct 30 settlement, down 17.4% from the prior report (14.2% of float, 1.1 days to cover).
No reported quarters with price history yet.
Percentile among 139 companies (100 = best)
Industry medians: 6-month return −24.5%, revenue growth +4.6%, net margin −221.0%, P/E 19.3×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| IRLAIRulya Therapeutics | $39.78 | +3.78% | — | — | — | — | $431.3M | |
| TECXTectonic Therapeutic | $21.04 | −4.19% | −29.4% | — | — | — | $411.3M | Compare |
| TVGNTevogen | $5.72 | −4.67% | −39.3% | — | — | — | $387.6M | Compare |
| FENCFennec Pharmaceuticals | $10.90 | +2.44% | +18.0% | +85.2% | 11.0% | — | $383.8M | Compare |
| ALECAlector | $2.45 | −6.84% | +6.5% | +4895.9% | 76.5% | 8.9 | $364.7M | Compare |
| CCCCC4 Therapeutics | $2.77 | −4.15% | −23.7% | −24.6% | −257.9% | — | $363.7M | Compare |
| RGNXREGENXBIO | $8.03 | −5.19% | +28.6% | −69.2% | −444.6% | — | $531.0M | Compare |
| SRZNSurrozen | $31.67 | −0.66% | +6.0% | −100.0% | — | — | $554.1M | Compare |
| ENTXEntera Bio | $3.22 | 0.00% | +143.9% | — | — | — | $560.7M | Compare |
No recent articles focused on IRulya Therapeutics.
IRulya Therapeutics Inc is committed to transforming the lives of patients with serious, underserved diseases by developing disease-modifying therapies. The company is currently developing LAM-001 for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD), bronchiolitis obliterans syndrome post-lung transplant (BOS), and sarcoidosis-associated pulmonary hypertension (SAPH). A Phase 2a study in PH patients has been completed; a Phase 2 clinical study in BOS patients is ongoing; a Phase 2b clinical study in PH-ILD is ongoing; and a Phase 2 clinical study in SAPH is ongoing.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
